| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
LUNG TRANSPLANTATION |
1 Transplantation and Immunobiology Group, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK
2 Department of Medical Microbiology, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK
3 Department of Medical Microbiology, University of Edinburgh, Edinburgh EH8 9AG, UK
4 Biomolecular Sciences Group, School of Pharmacy, Queen’s University, Belfast BT9 7BL, UK
Correspondence to:
Correspondence to:
Dr A De Soyza
William Leech Centre, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK; anthony.de-soyza{at}ncl.ac.uk
Background: It has previously been reported that patients infected with Burkholderia cenocepacia (genomovar III) before lung transplantation have a poorer outcome than those with other B cepacia complex infections.
Methods: An extensive study was conducted to determine the prevalence and clonality of B cepacia complex genomovars isolated from patients referred for transplant assessment between 1989 to the present and, where appropriate, whether strain type was related to transplant outcome.
Results: Isolates from 29 patients were identified as B cepacia complex organisms by molecular analysis. Thirteen patients (45%) were infected with the highly transmissible ET-12 strain of B cenocepacia recA lineage III-A, while all remaining patients were infected with genetically unique B cenocepacia, B multivorans, and B vietnamiensis strains. All previously reported deaths following transplantation were associated with ET-12 infection.
Conclusions: The ET-12 strain is the predominant cause of B cenocepacia infections in patients with cystic fibrosis referred to our pulmonary transplant centre and is associated with poor transplant outcomes using standard treatment regimens.
Keywords: Burkholderia cepacia complex; lung transplantation; cystic fibrosis; clonality
This article has been cited by other articles:
|
|
 |
|
  T. Ierano, A. Silipo, L. Sturiale, D. Garozzo, H. Brookes, C M A. Khan, C. Bryant, F K. Gould, P. A Corris, R. Lanzetta, et al. The structure and proinflammatory activity of the lipopolysaccharide from Burkholderia multivorans and the differences between clonal strains colonizing pre and posttransplanted lungs Glycobiology, November 1, 2008; 18(11): 871 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Boussaud, R Guillemain, D Grenet, N Coley, R Souilamas, P Bonnette, and M Stern Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres Thorax, August 1, 2008; 63(8): 732 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Soyza, A. Silipo, R. Lanzetta, J. R. Govan, and A. Molinaro Review: Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides Innate Immunity, June 1, 2008; 14(3): 127 - 144. [Abstract] [PDF]
|
|
|
|
 |
|
 J. F. Turton, N. Arif, D. Hennessy, M. E. Kaufmann, and T. L. Pitt Revised Approach for Identification of Isolates within the Burkholderia cepacia Complex and Description of Clinical Isolates Not Assigned to Any of the Known Genomovars J. Clin. Microbiol., September 1, 2007; 45(9): 3105 - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Elborn Practical Management of Cystic Fibrosis Chronic Respiratory Disease, July 1, 2006; 3(3): 161 - 165. [PDF]
|
|
|
|
|
|
S. Campana, G. Taccetti, N. Ravenni, F. Favari, L. Cariani, A. Sciacca, D. Savoia, A. Collura, E. Fiscarelli, G. De Intinis, et al. Transmission of Burkholderia cepacia Complex: Evidence for New Epidemic Clones Infecting Cystic Fibrosis Patients in Italy J. Clin. Microbiol., October 1, 2005; 43(10): 5136 - 5142. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
